Analysts expect ARS Pharmaceuticals to report a $0.54 loss per share and $22.12M revenue for Q1 2026.
ARS Pharmaceuticals (SPRY) will release Q1 2026 earnings on May 15 before the market opens. The consensus estimate projects a loss of $0.54 per share, reflecting a 54.3% year-over-year decline, while revenue is expected to reach $22.12M, up 177.5% from the same period last year.
Over the past three months, EPS estimates for the quarter have been adjusted, though specific revisions were not detailed. The company’s revenue growth contrasts with its continued losses, highlighting a period of expansion amid financial challenges.
No immediate market reaction details were provided ahead of the announcement.